To investigate the sequential paclitaxel combined with carboplatin in the treatment of elderly patients with cervical cancer and evaluate the clinical effects and analyze the best treatment for elderly patients with cervical cancer. Methods:A total of 102 cases of elderly patients with cervical cancer in Liaohe Oilfield General Hospital were selected from April 2015 to April 2017. According to the different treatment methods，they were randomly divided into the control group(49 cases)and the observation group(53 cases). The control group was given IMRT treatment. The experimental group，based on the control group，were added with paclitaxel combined with carboplatin. The lesions cancer cell proliferation，routine blood test and tumor marker changes were observed before the treatment and 4 cycles after treatment. The adverse reaction and efficacy were recorded within 4 cycles. Results:In the observation group，RBC(6.71±0.43)×1012/L，HCT(41.92±1.82)%，PLT(78.15±3.15)×109/L，N(51.47±1.42)%，WBC(8.41±0.87)×109/L were significantly lower than that of the control group. HGB(160.62±9.45)g/L was significantly higher than that of the control group(P<0.05); In the observation group，SCC(1.15±0.88)ng/mL，TPS(30.62±3.16)mU/mL，CA19-9(21.92±1.14)U/mL，Cyfra21-1(26.71±0.97)ng/mL，CEA(1.47±0.59)μg/mL，TPA(97.41±8.73)U/L，CA125(20.46±1.59)U/mL were significantly lower than that of the control group(P<0.05); In the observation group，B7-H4(121.81±9.14)，HIF-1α(126.64±10.97)，Sp2(130.47±11.59)，PCNA(120.46±10.59)were significantly lower than that of the control group. PTEN(81.73±4.92)，FHIT(80.78±4.16)，STC1(77.01±2.73)were significantly higher than that of the control group(P<0.05); In the experimental group，RR(64.15%)，DCR(96.23%)were significantly higher than that of the control group，which are(48.98%)，(85.71%)(P<0.05); The total score of TCM symptom score in the experimental group(4.46±0.59)was significantly lower than that of the control group(6.97±0.45)(P<0.05). There was no significant difference between the experimental group and the control group in the gastrointestinal reaction，urinary system，bone marrow suppression(P>0.05). Conclusion:For elderly patients with cervical cancer，the IMRT sequential paclitaxel combined with carboplatin can be used. Compared with paclitaxel and carboplatin treatment，it can improve the efficacy，reduce the adverse effects，and promote the recovery of blood routine and tumor markers as well as proliferation the lesions of cancer cells.